Pharmaceutical - Baxter International


Current filters:

Baxter International

Popular Filters

Baxter exceeds own predictions in 2nd-quarter

Baxter exceeds own predictions in 2nd-quarter


US drugmaker Baxter International reported strong growth across its global franchises in the second quarter…

Baxter InternationalFinancialFundamental analysisPharmaceuticalUSAValuation

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients


US health care company Baxter International as released encouraging top-line results from a Phase III…

BAX 111Baxter InternationalHematologyPharmaceuticalResearch

Baxter to split, creating two separate health care companies

Baxter to split, creating two separate health care companies


News that USA-based Baxter International plans to create two separate, independent global health care…

Baxter InternationalManagementMergers & AcquisitionsPharmaceutical

Onconova tanks, as lead drug rigosertib fails in Ph III MDS study

Onconova tanks, as lead drug rigosertib fails in Ph III MDS study


US biotech firm Onconova Therapeutics saw its shares plunge 37% to $8.70 in pre-market trading yesterday…

Baxter InternationalOncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Baxter restructures deal with Xenetic Biosciences


USA-based Baxter International has restructured its ongoing agreement with Xenetic Biosciences for the…

BAX 826Baxter InternationalHematologyLicensingPharmaceuticalResearchXenetic Biosciences

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B


US drugmaker Baxter International has received approval from the US Food and Drug Administration for…

Baxter InternationalFeibaHematologyPharmaceuticalRegulation

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency


USA-based Baxter International has completed submission of an amended biologics license application to…

Baxter InternationalHalozyme TherapeuticsHyQviaImmunologicalsNorth AmericaPharmaceuticalRegulationUSA

Baxter buys exclusive rights to CTI’s cancer drug pacritinib


USA-based companies Baxter International and Cell Therapeutics have entered into an exclusive worldwide…

Baxter InternationalCell TherapeuticsFinancialGlobalLicensingOncologypacritinibPharmaceutical

Acquisition costs take toll on Baxter’s 3rd-qtr financials


USA-based Baxter International has posted solid financial results for the third quarter of 2013, showing…

Baxter InternationalFinancialHematologyPharmaceutical

EU Commission puts conditions on Baxter's acquisition of Gambro


The European Commission has authorized the proposed $4 billion acquisition of privately-held Swedish…

Baxter InternationalGambroMergers & AcquisitionsPharmaceutical

FDA backs Baxter's Rixubis for hemophilia B; Breakthrough status for GSK's drisapersen


The US Food and Drug Administration yesterday (June 27) approved Baxter International's (NYSE: BAX) Rixubis…

Baxter InternationaldrisapersenGlaxoSmithKlineNorth AmericaPharmaceuticalRare diseasesRegulationRixubis

Baxter shares dip as Alzheimer's drug fails to meet Ph III endpoints


Shares of US drugmaker Baxter International (NYSE: BAX) fell 2.5% to $68.58 in New York trading on May…

Baxter InternationalGammagardNeurologicalPharmaceuticalResearch

Ipsen and Inspiration Biopharma in deal with Baxter for OBI-1


French drugmaker Ipsen (Euronext: IPN) and privately-held US firm Inspiration Biopharmaceuticals have…

Baxter InternationalIB1001Inspiration BiopharmaceuticalsIpsenMergers & AcquisitionsOBI-1Pharmaceutical

Baxter to expand renal therapies range with $4 billion buy of Gambro


Confirming recent rumors and speculation, Baxter International (NYSE:BAX ) said yesterday it has entered…

Baxter InternationalGambroMergers & AcquisitionsNephrology and HepatologyPharmaceutical

Baxter in up to $565 million deal with Onconova for rigosertib


US companies Baxter International (NYSE: BAX) and privately-held biotech Onconova Therapeutics have entered…

Baxter InternationalEstybonEuropeLicensingOncologyOnconova TherapeuticsPharmaceuticalrigosertib

News briefs: setbacks for B-MS hep C drug; Baxter's HyQ


US drug major Bristol-Myers Squibb (NYSE: BMY) has suspended study drug administration in ongoing Phase…

Anti-viralsBaxter InternationalBMS-986094Bristol-Myers SquibbHyQImmunologicalsNorth AmericaPharmaceuticalRegulationResearch

Baxter's Gammagard shows potential in stabilizing Alzheimer's


The first report of long-term (three-year) stabilization of Alzheimer's disease symptoms with intravenous…

Baxter InternationalGammagardNeurologicalPharmaceuticalResearch

Baxter to invest over $1 billion on new facility; post 1st-qtr results


USA-based Baxter International (NYSE:BAX) has announced plans to build a new state-of-the-art manufacturing…

Baxter InternationalFinancialPharmaceutical

EU Commission OKs Baxter Avian flu vaccine Vepacel; drops GSK probe


US drugmaker Baxter International (NYSE:BAX) says that the European Commission has granted marketing…

Anti-viralsBaxter InternationalEuropeGlaxoSmithKlineLegalPharmaceuticalRegulationSynthonVaccinesVepacel

Baxter to acquire Synovis


The USA’s Baxter International (NYSE: BAX) said yesterday that it has reached agreement to acquire…

Baxter InternationalMergers & AcquisitionsPharmaceuticalSynovis Life Technologies

Baxter pays $380 million to acquire drug delivery firm Baxa


USA-based Baxter International (NYSE: BAX) has entered into a definitive agreement to acquire Baxa Corp,…

Baxa CorpBaxter InternationalMergers & AcquisitionsPharmaceutical

Takeda and Daiichi Sankyo both get Japanese government grants for vaccine facilities


Japan’s largest drug company Takeda Pharmaceuticals (TYO: 4502) and fellow major Daiichi Sankyo…

Anti-viralsAsia-PacificBaxter InternationalDaiichi SankyoFinancialPharmaceuticalTakeda Pharmaceuticals

Company Spotlight



Back to top